Table 1.
Characteristic | Delamanid (OPC-67683) | Pretomanid (PA-824) |
---|---|---|
Developed by: | Otsuka Pharmaceutical Co., Ltd. | PathoGenesis Corporation |
Chemical namea: | (2R)-2-methyl-6-nitro-2-[(4-{4-[4-(trifluoromethoxy)phenoxy] piperidin-1-yl}phenoxy)methyl]-2,3-dihydroimidazo[2,1-b][1,3]oxazole | (6S)-2-nitro-6-[[4-(trifluoromethoxy)phenyl]methoxy]-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine |
Chemical structurea | ||
Mechanism of action | 1. Inhibition of mycolic acid synthesis (methoxymycolates and ketomycolates) | 1. Inhibition of mycolic acid synthesis (ketomycolates) |
2. Respiratory poisoning (reactive intermediates are yet to be identified) | 2. Respiratory poisoning by the release of reactive nitrogen species upon metabolic activation |
Information extracted from https://pubchem.ncbi.nlm.nih.gov.